HWM
RNAM

Hemington Wealth Management’s Avidity Biosciences RNAM Stock Holding History

Hemington Wealth Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$0 Buy
+7
New +$283 ﹤0.01% 1688

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hemington Wealth Management's RNAM Position: Q3 2025 in Review

Hemington Wealth Management opened a new position in Avidity Biosciences (RNAM) in Q3 2025: 7 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1688 among its holdings.

272 funds tracked by Wall St. Rank hold RNAM as of Q3 2025.

  • Hemington Wealth Management held 7 shares of Avidity Biosciences worth $0 as of Q3 2025.
  • Avidity Biosciences was a new Hemington Wealth Management position in Q3 2025.
  • Avidity Biosciences made up ﹤0.01% of Hemington Wealth Management's portfolio in Q3 2025, its #1688 holding.
  • 272 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.